What is Repare Therapeutics?
Repare Therapeutics is a clinical-stage precision oncology firm distinguished by its proprietary synthetic lethality approach. The company leverages its advanced genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies. Its focus is on addressing genomic instability, particularly DNA damage repair mechanisms, aiming to create novel treatments for various cancers. The company's scientific foundation is built on identifying and exploiting vulnerabilities in cancer cells that are distinct from those in healthy cells, a strategy that holds promise for more effective and less toxic cancer interventions.
How much funding has Repare Therapeutics raised?
Repare Therapeutics has raised a total of $150.5M across 2 funding rounds:
Series A
$68M
Series B
$82.5M
Series A (2017): $68M with participation from Fonds de solidaritu00e9 FTQ, MPM Capital, Celgene Switzerland, and Versant Ventures
Series B (2019): $82.5M led by Versant Ventures, BVF Partners L.P, OrbiMed, Fonds de solidarité FTQ, Logos Capital, Cowen Healthcare Investments, Redmile, BDC Capital, and MPM Capital
Key Investors in Repare Therapeutics
Versant Ventures
Versant Ventures is a prominent venture capital firm specializing in the biotechnology sector, with a strong track record of building and funding innovative companies. They focus on early-stage ventures and leverage extensive scientific and investment expertise to drive therapeutic discoveries.
OrbiMed
OrbiMed is a global investment firm dedicated to the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health. They provide strategic investment and operational support to companies at various stages of development.
Cowen Healthcare Investments
Cowen Healthcare Investments is part of a diversified financial services firm, providing investment banking, research, and investment management services. They focus on supporting companies within the healthcare industry, contributing strategic financial backing.
What's next for Repare Therapeutics?
With substantial enterprise-level backing, Repare Therapeutics is poised to accelerate its clinical development programs and further enhance its discovery engine. The strategic capital infusion is expected to fuel the advancement of its lead programs through clinical trials and expand its research into new synthetic lethality targets. The company's focus on precision oncology and its unique platform suggest a strategic direction aimed at addressing unmet needs in cancer treatment, potentially leading to significant breakthroughs and market impact. Future growth will likely involve expanding its therapeutic pipeline and forging strategic partnerships to maximize the commercial potential of its discoveries.
See full Repare Therapeutics company page
